HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
MWN-AI** Summary
HeartSciences Inc. (Nasdaq: HSCS; HSCSW), a healthcare information technology company focused on advancing electrocardiography through artificial intelligence, reported its fiscal third quarter 2026 financial results and provided a business update on March 16, 2026. For the period ending January 31, 2026, the company continues to progress in the commercialization of its MyoVista Insights™ healthcare IT platform while recently submitting its MyoVista® wavECG™ device for FDA 510(k) premarket clearance.
HeartSciences highlighted key achievements during its third quarter. The MyoVista Insights platform, classified as a Medical Device Data System (MDDS) and exempt from extensive regulatory requirements, has received phased upgrades, including a significant version release in March 2026 that enhances mobile functionality, reporting, and interoperability across large healthcare systems. These upgrades are designed to facilitate faster commercial rollout and establish essential reference sites, with early commercial traction noted through endorsements from a hospital network.
Despite no meaningful revenue reported for FQ3 2026, HeartSciences outlined its objectives to generate initial revenues and foster an AI-ECG marketplace through its platform, which will support third-party algorithms. Management anticipates securing key customer wins as it dives into the expansive AI-ECG market, projected to be worth billions.
CEO Andrew Simpson expressed confidence in the company's trajectory, highlighting progress toward 2026 goals and the significance of the FDA submission as part of HeartSciences' strategy to modernize ECG practices. As of January 31, 2026, the company had approximately $3.4 million in cash and $2.7 million in shareholder equity. Full financial results are detailed in the Quarterly Report filed with the SEC.
MWN-AI** Analysis
HeartSciences Inc. reported its Fiscal Q3 2026 results on March 16, revealing a pivotal chapter in its journey to commercialize the MyoVista Insights healthcare IT platform. Although the company reported no meaningful revenue during this quarter, the strategic advancements, particularly the submission of the MyoVista wavECG™ device for FDA clearance, position HeartSciences favorably within the burgeoning AI-integrated ECG market.
Investors should note that the regulatory classification of the MyoVista Insights platform as a Medical Device Data System (MDDS) allows for a faster go-to-market timeline, removing some hurdles often faced by FDA-regulated products. The platform is designed to improve clinical efficiency significantly and generate per-test SaaS revenues. With the exciting potential of an AI-ECG marketplace to integrate third-party algorithms, HeartSciences stands to capture a substantial share of a multi-billion-dollar sector as hospitals increasingly adopt AI technologies.
Furthermore, the recent significant upgrades to the MyoVista Insights platform, which include mobile capability and enhanced interoperability, signal a proactive approach to meet industry needs. The alignment with large health systems establishes a solid foundation for future revenue realization and client installations, especially as the company anticipates announcing key customer wins this year.
While the lack of current revenue might present an initial red flag for investors, the upcoming ACC Annual Scientific Session could catalyze deeper market engagement and investor interest. This event offers a dual opportunity to showcase the platform and outline the commercialization strategy.
In conclusion, HeartSciences is navigating a challenging landscape with strength through regulatory and technological advancements. Investors should consider the long-term potential of the company as it prepares to disrupt the traditional cardiac healthcare landscape, balancing potential risks with promising growth opportunities.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update.
Third Quarter and Recent Highlights
During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.
MyoVista Insights™ Healthcare IT Software Platform
- Regulatory classification. MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements than medical devices and is exempt from FDA 510(k) clearance. As a result, organizational costs and time to commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.
- Platform advancement. Since its early-adopter launch in 2025, the Company has implemented phased upgrades to MyoVista Insights. On March 13, 2026, HeartSciences released a significant version upgrade ahead of the American College of Cardiology (“ACC”) Annual Scientific Session, where the Company will exhibit and publicly introduce the platform to the broader cardiology and healthcare IT community. The upgrade includes mobile phone viewing, reporting enhancements, and significant interoperability improvements designed to support deployment across large health systems.
- Commercial traction. During 2026 the Company’s objectives include establishing key reference sites and generating initial revenues. HeartSciences has already made commercial progress with reference installations and endorsement from a hospital network. Early feedback has been compelling, and the Company is currently in discussions with multiple health systems regarding deployment. Management expects to announce several key customer wins during 2026.
- AI-ECG marketplace opportunity. In addition to generating per-test SaaS revenues as a secure cloud-based ECG data management system, MyoVista Insights is purpose-built to enable the integration of AI-ECG algorithms directly into routine clinical practice through an AI-ECG marketplace. The platform is designed to host third-party algorithms alongside HeartSciences’ own technologies. The Company is currently in discussions with several potential partners to host AI algorithms and believes this model positions HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity while reducing the cost and time required for algorithm development and regulatory clearance.
- Investor demonstration. Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the Company plans to host an investor call to demonstrate the platform and provide additional detail regarding its commercialization strategy and market opportunity.
MyoVista® wavECG™ Device
- The Company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025.
- HeartSciences elected to separate the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the American Society of Echocardiography (“ASE”) regarding the assessment of Left Ventricular Diastolic Dysfunction (“LVDD”), including revised age-based thresholds for cardiac relaxation (e’).
Management Commentary
Andrew Simpson, Chief Executive Officer of HeartSciences, said, “We are making strong progress toward our 2026 objectives, including establishing reference sites, commencing revenue generation for MyoVista Insights, making AI algorithms available on the platform, and achieving best-in-class interoperability across hospital systems.”
Mr. Simpson added, “The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone and advances our broader strategy to modernize ECG through the integration of artificial intelligence.”
Fiscal Third Quarter 2026 Financial Results
HeartSciences reported no meaningful revenue for FQ3 2026 as the Company continues to focus on commercialization of the MyoVista Insights platform.
As of January 31, 2026, the Company had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity.
Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, which has been filed with the U.S. Securities and Exchange Commission and is available on the Company’s website at www.heartsciences.com.
About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com
FAQ**
How does HeartSciences plan to leverage the partnership with Heart Test Laboratories Inc. regarding their warrant HSCSW to enhance the commercialization of MyoVista Insights?
What specific metrics will HeartSciences use to measure the effectiveness of the MyoVista Insights platform once deployed through its agreement with Heart Test Laboratories Inc. and its warrant HSCSW?
In light of the regulatory framework for MyoVista Insights, how does HeartSciences anticipate the Heart Test Laboratories Inc. Warrant HSCSW will impact investor confidence and market traction?
What role does Heart Test Laboratories Inc. warrant HSCSW play in facilitating collaboration with other health systems for the deployment of MyoVista Insights?
**MWN-AI FAQ is based on asking OpenAI questions about Heart Test Laboratories Inc. (NASDAQ: HSCS).
NASDAQ: HSCS
HSCS Trading
-2.04% G/L:
$2.64 Last:
540 Volume:
$2.64 Open:
